Every few weeks it seems scientists are discovering new compounds in cannabis promising medical miracles. For researchers at GW Pharmaceuticals, a cousin of CBD called CBDV, or cannabidivarin, could be the next big thing in autism treatment.
GW Pharmaceuticals already produces the only FDA-approved drug derived from CBD for use in epilepsy patients in the United States. And since autism and epilepsy share some neurological features, they figured they should explore autism and weed too. And the preliminary results using animal are encouraging.
CBDV “had important effects on social functioning, decreasing seizures, increasing cognitive function and reducing compulsive behaviour,” according to a recent report by CNN.